• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Genomic profiling of anaplastic meningioma identifies recurrent genetic alterations with relevance to lower-grade meningioma.

作者信息

Cimino P J, Yoda R A, Wirsching H-G, Warrick J I, Dorschner M O, Ferreira M

机构信息

Department of Pathology, Division of Neuropathology, University of Washington School of Medicine, Seattle, WA, USA.

Division of Human Biology, and Seattle Tumor and Translational Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

出版信息

Neuropathol Appl Neurobiol. 2019 Feb;45(2):179-182. doi: 10.1111/nan.12487. Epub 2018 May 8.

DOI:10.1111/nan.12487
PMID:29675951
Abstract
摘要

相似文献

1
Genomic profiling of anaplastic meningioma identifies recurrent genetic alterations with relevance to lower-grade meningioma.间变性脑膜瘤的基因组分析确定了与低级别脑膜瘤相关的复发性基因改变。
Neuropathol Appl Neurobiol. 2019 Feb;45(2):179-182. doi: 10.1111/nan.12487. Epub 2018 May 8.
2
An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures.弥漫性间变性脑膜瘤的综合基因组分析确定了预后分子特征。
Sci Rep. 2018 Sep 10;8(1):13537. doi: 10.1038/s41598-018-31659-0.
3
First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.对2型神经纤维瘤病相关的I级和II级脑膜瘤体细胞突变负担的初步见解：一项对两例临床表现差异极大的颅脑膜瘤的病例报告及综合基因组研究。
BMC Cancer. 2017 Feb 13;17(1):127. doi: 10.1186/s12885-017-3127-6.
4
High-grade meningiomas: biology and implications.高级别脑膜瘤：生物学特性及其影响。
Neurosurg Focus. 2018 Apr;44(4):E2. doi: 10.3171/2017.12.FOCUS17756.
5
Integrative genomic analysis identifies CCNB1 and CDC2 as candidate genes associated with meningioma recurrence.综合基因组分析确定CCNB1和CDC2为与脑膜瘤复发相关的候选基因。
Cancer Genet. 2011 Oct;204(10):536-40. doi: 10.1016/j.cancergen.2011.08.019.
6
Mutational Analysis of Recurrent Meningioma Progressing From Atypical to Rhabdoid Subtype.从非典型性到横纹肌样亚型复发性脑膜瘤的突变分析
World Neurosurg. 2017 Jan;97:754.e1-754.e6. doi: 10.1016/j.wneu.2016.10.047. Epub 2016 Oct 15.
7
Clinical potential of meningioma genomic insights: a practical review for neurosurgeons.脑膜瘤基因组见解的临床潜力：神经外科医生的实用综述。
Neurosurg Focus. 2018 Jun;44(6):E10. doi: 10.3171/2018.2.FOCUS1849.
8
Comparative genomic hybridization analysis of genetic alterations associated with malignant progression of meningioma.与脑膜瘤恶性进展相关的基因改变的比较基因组杂交分析
J Neurooncol. 1999 Jan;41(2):167-74. doi: 10.1023/a:1006086723607.
9
High resolution genomic profiling and classical cytogenetics in a group of benign and atypical meningiomas.一组良性和非典型脑膜瘤的高分辨率基因组分析与经典细胞遗传学研究
Cancer Genet. 2011 Oct;204(10):541-9. doi: 10.1016/j.cancergen.2011.10.007.
10
Association of Genetic Predisposition With Solitary Schwannoma or Meningioma in Children and Young Adults.儿童和青年中遗传易感性与孤立性神经鞘瘤或脑膜瘤的关联。
JAMA Neurol. 2017 Sep 1;74(9):1123-1129. doi: 10.1001/jamaneurol.2017.1406.

引用本文的文献

1
null genotype underpins recurrence of meningiomas.无特定基因型是脑膜瘤复发的基础。
Front Oncol. 2024 Dec 12;14:1506708. doi: 10.3389/fonc.2024.1506708. eCollection 2024.
2
Clinicopathological significance of concurrent ErbB receptor expression in human meningioma.人脑膜瘤中ErbB受体共表达的临床病理意义
Mol Clin Oncol. 2023 Aug 23;19(4):79. doi: 10.3892/mco.2023.2675. eCollection 2023 Oct.
3
Molecular landscapes of longitudinal NF2/22q and non-NF2/22q meningiomas show different life histories.NF2/22q 和非 NF2/22q 脑膜瘤的纵向分子图谱显示出不同的生命史。
Brain Pathol. 2023 May;33(3):e13120. doi: 10.1111/bpa.13120. Epub 2022 Sep 27.
4
Comparative genomic analysis of driver mutations in matched primary and recurrent meningiomas.配对的原发性和复发性脑膜瘤中驱动基因突变的比较基因组分析。
Oncotarget. 2019 May 28;10(37):3506-3517. doi: 10.18632/oncotarget.26941.